ARTICLE | Clinical News
Ribozyme starts Phase II Angiozyme trial
June 20, 2001 7:00 AM UTC
RZYM and partner Chiron (CHIR) started a U.S. Phase II study of RZYM's Angiozyme ribozyme targeted to the VEGF receptor in 75 patients with metastatic colorectal cancer. The trial will evaluate Angioz...